Evidence map›Paper›PMID 42058596›Full record

ArticleMolecular therapy. Oncology2026

LMTK3 as a spatially regulated and stage-dependent biomarker in epithelial ovarian tumorigenesis.

Ella Ittner, Lucas Werner, Hugo Swenson, Anna Linder, Karin Sundfeldt, Ghassan Saed, Per Karlsson, Toshima Z Parris, Anikó Kovács, Khalil Helou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ella IttnerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Lucas WernerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Hugo SwensonDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anna LinderSahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Karin SundfeldtSahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Ghassan SaedDepartment of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
Per KarlssonDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Toshima Z ParrisDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anikó KovácsRegion Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Pathology, Gothenburg, Sweden.
Khalil HelouDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lemur tyrosine kinase 3 (LMTK3) has been implicated in cancer prognosis and progression. While its role in early-stage epithelial ovarian cancer (EOC) has been explored, the dynamics of its subcellular expression across the disease spectrum remain unclear. LMTK3 protein expression was assessed by immunohistochemistry on tissue microarrays comprising benign, borderline, and malignant ovarian tumors (

Indexed as

immunohistochemistrylemur tail kinase 3lemur tyrosine kinase 3LMTK3MT: Regular Issueovarian cancerprognostic biomarkertumor initiationtumor progression

Identifiers

PMID42058596
PMCPMC13123347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.